# US 2019/0375734 A1 · Process and crystalline forms of lumacaftor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375734 A1
- Document ID: US20190375734A1
- Status: Published application
- Kind: A1
- Application number: 16/476,486
- Filed: 2018-01-06
- Published: 2019-12-12
- Earliest claimed: 2017-01-09
- Assignees: Laurus Labs Limited
- Applicants: Laurus Labs Limited
- Inventors: Ravindra Babu Bollu; Prasanta Kumar Dalasingh; Sushmita Dwarampudi; Chandrahasa Reddy Annem; Uma Maheswer Rao Vasireddi
- Web page: https://patentgrep.com/patent/US20190375734A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention generally relates to crystalline forms of Lumacaftor, processes for its preparation and pharmaceutical compositions thereof. The present invention also relates to an improved process for preparation of Lumacaftor.

## Claims

### Claim 1

Lumacaftor Form-LA1 characterized by X-Ray diffraction (XRD) pattern having one or more peaks at about 4.3, 8.7, 12.9, 14.8, 17.5, 17.7, 18.7, 19.3, 20.3, 21.8, 22.2, 22.8, 23.5, 23.6, 25.7, 26.4, 28.0, 29.8, 33.0, 36.9, 38.2, 40.1 and 43.7±0.2° 2θ.

### Claim 2 (depends on 1)

Lumacaftor Form-LA1 of claim 1, further characterized by a powder X-ray diffraction (PXRD) pattern substantially in accordance with FIG. 1.

### Claim 3 (depends on 1)

Lumacaftor Form-LA1 of claim 1, further characterized by differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 2.

### Claim 4 (depends on 1)

Lumacaftor Form-LA1 of claim 1, further characterized by thermo gravimetric analysis (TGA) curve substantially in accordance with FIG. 3.

### Claim 5 (depends on 1)

Lumacaftor Form-LA1 of claim 1, further characterized by differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 2 and a thermo gravimetric analysis (TGA) curve substantially in accordance with FIG. 3.

### Claim 6

A process for the preparation of lumacaftor Form-LA1, comprising:
a) dissolving lumacaftor in water and a base at a suitable temperature,
b) optionally, cooling the solution to less than 25° C., and
c) isolating the lumacaftor Form-LA1.

### Claim 7 (depends on 6)

The process of claim 6, wherein the base is selected from one or more of the group consisting of ammonium bases, alkali metal hydroxides, alkali metal alkoxides, alkali metal bicarbonates, organic bases and or mixture thereof.

### Claim 8 (depends on 7)

The process of claim 7, wherein the base is ammonium hydroxide, ammonium carbonate, ammonium bicarbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, isopropyl ethylamine, diisopropyl amine, diisopropyl ethylamine, or mixture thereof.

### Claim 9 (depends on 8)

The process of claim 8, wherein the base is ammonium hydroxide.

### Claim 10 (depends on 6)

The process of claim 6, wherein the step a) is carried out at a temperature of about 50° C. to about 80° C.

### Claim at position 11

11-24. (canceled)

### Claim 25

An improved process for the preparation of lumacaftor of Formula I,
comprising:
reacting a compound of Formula II with a compound of Formula III in the presence of a palladium catalyst and a base in a solvent to obtain the lumacaftor, wherein ‘X’ represent a leaving group.

### Claim 26 (depends on 25)

The process of claim 25, wherein the leaving group is selected from one of the group consisting of chloro, bromo, iodo, triflate or tosylate.

### Claim 27 (depends on 26)

The process of claim 26, wherein the leaving group is chloro or bromo.

### Claim 28 (depends on 25)

The process of claim 25, wherein the palladium catalyst is selected from one of the group consisting of tetrakis (triphenylphosphine) palladium(0), tetrakis(tri(otolyl)phosphine)palladium(0),tris(dibenzylideneacetone) dipalladium(0),[1,1′-bis(diphenyl phosphino) ferrocene] dichloropalladium (II) or palladium(II) acetate.

### Claim 29 (depends on 25)

The process of claim 25, wherein the base is selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, isopropyl ethylamine, diisopropyl amine, diisopropyl ethylamine, N-methyl morpholine, piperidine, or pyridine.

### Claim 30 (depends on 25)

The process of claim 25, wherein the solvent is selected from the group consisting of tetrahydrofuran, 2-methyl tetrahydrofuran, dimethyl ether, diethyl ether, diisopropyl ether, methyl tertiary butyl ether, 1,4-dioxane, 1,2-dimethoxy ethane, dimethyl formamide, dimethyl acetamide, N-methyl pyrrolidinone, dimethyl sulfoxide, toluene, xylene water, or mixture thereof.

### Claim 31 (depends on 25)

The process of claim 25, wherein the palladium catalyst is tetrakis (triphenylphosphine) palladium(0); the base is potassium carbonate; and the solvent is dimethyl formamide.

### Claim 32 (depends on 25)

The process of claim 25, wherein the reaction is carried out at a temperature of about 85° C. to about 105° C.

### Claim at position 20

33-44. (canceled)

### Claim 45

A process for the preparation of lumacaftor Form I, comprising:
a) suspending lumacaftor Form-LA1 in a solvent; and
b) isolating the lumacaftor Form I.

### Claim 46 (depends on 45)

The process of claim 45, wherein the solvent is water.

### Claim 47 (depends on 45)

The process of claim 45, wherein the step a) is carried out at a temperature of about 65° C. to about 75° C.

### Claim 48 (depends on 1)

A pharmaceutical composition comprising:
lumacaftor according to claim 1; and
at least one pharmaceutically acceptable excipient.
